The impella micro-axial flow catheter is safe and effective for treatment myocarditis complicated by cardiogenic shock: An analysis from the global cVA registry

Document Type

Conference Proceeding

Publication Date


Publication Title

J Card Fail


Background: Myocarditis complicated by cardiogenicshock (Myo-CS) remain complex clinical problem. Theuse of acute mechanical circulatory support devices cardiogenic shock is growing. We explored theclinical utility of Impella tra valvular micro-axial flowcatheters in the setting of Myo-CS. Methods: We retrospectiv analyzed data from 21 sites within thecVAD registry, an ongoing multicenter volu tary registry at sites in North America and Europe that have used Impella in >10 patien Myocarditis was defined by endomyocardial biopsy in 34% (n= 11) or by clinical hist without angiographic evidence of coronary disease (n = 23). Results: A total of 34 tients who received Impella support for Myo-CS were identified. Mean age was 42 ± years with 17 males. Baseline mean cardiac index was 1.8 ± 0.5 L·min-1·m-2, pulm nary capillary wedge pressure was 25 ± 7 mmHg, and right atrial pressure w 22 ± 3 mmHg. Mean lactate was 27 ± 31 mg·dL-1. 32% (n= 11) of patients required intra-aortic balloon pump and 85% (n = 29) were requiring vasopressor/inotrope therapy prior to Impella placement. The Impella 2.5, CP, and 5.0 were used in 41% (n = 14), 35% (n = 12) and 24% (n = 8) respectively. Impella support was used for a mean duration of 90.56 ± 74.26 hours. Mean left ventricular ejection fraction improved fromadmission to discharge (18 ± 10 vs 37 ± 20%, P = .001). In-hospital mortality was 38% (n = 13), 47% (n = 16) of patients were discharged alive with 94% recovering without need for further device therapy (Figure). Conclusions: This is the largest analysis of Impella-supported myocarditis cases to date. Theuse of the Impella appears to be safe and effectivein the settings of myocarditis complicated bycardiogenic shock.





First Page


Last Page


This document is currently not available here.